| Michael E. Castagna |
Michael E. Castagna is currently the Chief Executive Officer & Director at MannKind Corp. He is also a Director at Pet Partners. Previously, he held positions as the Executive Director-Immunology Franchise at Bristol Myers Squibb Co. from 2010 to 2012, Director at Pharmasset, Inc. in 2005-2006, Vice President-Global Commercial at Amgen, Inc. from 2012 to 2016, and Vice President & Head-Biopharmaceuticals at Sandoz, Inc. from 2009 to 2010. He also served as the VP & Head-North America Biopharmaceuticals at Novartis AG. Dr. Castagna obtained a doctorate degree from Massachusetts College of Pharmacy & Health Science in 2014, an MBA from The Wharton School of the University of Pennsylvania in 2005, and an undergraduate degree from Philadelphia College of Pharmacy in 2000. |
| Sanjay Singh |
Sanjay Singh is currently the Executive Vice President-Technical Operations at MannKind Corp. Prior to this, he worked as the SVP & Associate President-Technical Operations at Aurobindo Pharma Ltd. and as the President at Parenteral Drug Association. He holds an MBA from the Institute of Management Studies (Indore) and a graduate degree from L. M. College of Pharmacy. |
| James Samuel Shannon |
James Samuel Shannon is currently the Chairman at MannKind Corp., Kyowa Kirin Ltd., Impatients NV, Mytommorows, The Royal College of Physicians, ProQR Therapeutics NV, and Leyden Laboratories B.V. He previously held positions as the President, Chief Executive Officer & Director at Cerimon Pharmaceuticals, Inc., Independent Director at MannKind Corp., Non-Executive Director at Circassia Ltd., Independent Director at Horizon Therapeutics Plc, Director at Biotie Therapies Oy, Director at Xanodyne Pharmaceuticals, Inc., Independent Director at Endocyte, Inc., Director at Immodulon Therapeutics Ltd., Director at Arch Therapeutics, Inc., Director at ViiV Healthcare Ltd., Member-Supervisory Board at Crucell NV, Chief Medical Officer at GSK Plc, Senior Vice President-Clinical Development at Sterling Winthrop, Inc., Head-Drug Regulatory Affairs at Sandoz Ltd., and Global Head-Pharmaceutical Development at Novartis Pharma AG. He received his undergraduate, graduate, and doctorate degrees from Queen's University of Belfast. |
| Joseph Kocinsky |
Joseph Kocinsky is currently the Chief Technology Officer at MannKind Corp. He holds a Master's in Business Administration from Seton Hall University and completed his undergraduate and graduate degrees from New Jersey Institute of Technology. |
| Steven B. Binder |
Steven B. Binder's career history includes several positions in finance and strategic development. He is currently the Executive Vice President-Special Projects at MannKind Corp. Prior to his current role, he held the position of Vice President-Finance at Bristol Myers Squibb Co. from 2012 to 2013. From 2013 to 2016, he served as the Chief Financial Officer & Vice President at Stryker Corp. Before that, he was the Vice President-Finance at Bristol-Myers Squibb Pharmaceuticals Ltd. from 2008 to 2011. Additionally, he held the position of Vice President-Strategic Development at Oncology Therapeutics Network Corp. from 2001 to 2003 and Vice President-Finance at Bristol-Myers Squibb KK from 2003 to 2005. Mr. Binder obtained his undergraduate degree from Muhlenberg College in 1984. |
| Christopher B. Prentiss |
Christopher B. Prentiss is currently the Chief Financial & Accounting Officer at MannKind Corp. He previously worked as the Vice President-Finance & Controller at InterMune, Inc. from 2013 to 2015, and as the Controller at Dynavax Technologies Corp. from 2012 to 2013. Christopher also held the position of Controller at MannKind Corp. Additionally, he served as the Chief Financial Officer at Adamas Pharmaceuticals LLC from 2019 to 2021. Prior to that, Christopher worked as a Senior Manager at KPMG LLP from 1997 to 2005. He holds an MBA from Indiana University and an undergraduate degree from Loyola Marymount University. |
| Kevin Kaiserman |
Kevin Kaiserman is currently working as the Senior VP-Clinical Development & Medical Affairs at MannKind Corp. He is also a Member of the Pediatric Endocrine Society. In the past, he worked as a Member at the American Diabetes Association. Dr. Kaiserman holds a doctorate degree from Eastern Virginia Medical School. |
| Thomas Hofmann |
Founder of Aumapharma, Inc. and QrumPharma, Inc., Thomas Hofmann currently occupies the position of Chief Executive Officer at Aumapharma, Inc. and Chief Scientific Officer for MannKind Corp., Chief Executive Officer at QrumPharma, Inc. (a subsidiary of MannKind Corp.).
In his past career he held the position of Principal at Windtree Therapeutics, Inc., Principal at Pulmopharm GmbH, Chief Medical Officer & Head-Clinical Development at Vectura GmbH and Principal at Corus Pharma, Inc.
Dr. Hofmann received a doctorate from the University of Giessen. |
| Lauren M. Sabella |
Lauren M. Sabella is the founder of Tugboat Consulting Group, which was founded in 2009. She is currently the Chief Operating Officer & Executive Vice President at MannKind Corp. since 2023. Ms. Sabella's former positions include Chief Operating Officer at Acorda Therapeutics, Inc. from 2021 to 2022, Vice President-Commercial Development at Altus Pharmaceuticals, Inc. from 2006 to 2008, and Vice President-Sales-Eastern Zone at Boehringer Ingelheim Pharmaceuticals, Inc. from 2002 to 2006. Ms. Sabella received an undergraduate degree from Hofstra University. |
| Burkhard Blank |
Burkhard Blank is currently the Chief Medical Officer and EVP-Research & Development at MannKind Corp. Prior to this, he held the position of Chief Medical Officer and Head-Research & Development at Acorda Therapeutics, Inc. from 2016 to 2021. He also served as the Chief Executive Officer at Laurantis Pharma Oy in 2013-2014. Blank was the Chief Medical Officer & Executive Vice President at Altus Pharmaceuticals, Inc. from 2006 to 2009 and the SVP-Medicine & Drug Regulatory Affairs at Boehringer Ingelheim Pharmaceuticals, Inc. from 2001 to 2006. He has also worked at RIEMSER Pharma GmbH, Acorda Therapeutics, Inc., Mersana Therapeutics, Inc., Pharnext SA, and Herantis Pharma Oyj. Blank holds a doctorate degree from Philipps University of Marburg. |
| Stuart A. Tross |
Stuart A. Tross is currently the Chief People & Workplace Officer, Executive VP at MannKind Corp. Prior to this, he held the position of Senior Vice President-Human Resources at Amgen, Inc. from 2006 to 2016. Before that, he was the Vice President-Global Human Resources at Bristol Myers Squibb Co. and a Management Consultant at Towers Perrin, Inc. He also served as the Global Head-Human Resources at Mead Johnson & Co. LLC from 1998 to 2006. Dr. Tross holds a graduate and doctorate degree from Georgia Institute of Technology, an undergraduate degree from Cornell University, and a graduate degree from Spalding University, Inc. |
| Kent Kresa |
Kent Kresa is the founder of Northrop Grumman Corp. He currently holds multiple positions including Chairman at the California Institute of Technology, Vice Chairman at T-Ink, Inc., Independent Director at MannKind Corp., Director at Eisenhower Health, Director at W.M. Keck Foundation, Inc., Director at Los Angeles World Affairs Council, Director at Systems & Technology Research LLC, Director at FastDetect, Inc., Independent Director at NuScale Power Corp., Member-Managers Board at NuScale Power LLC, Principal at the University of California, Los Angeles, Member of the National Academy of Engineering, and Trustee at The John Randolph Haynes Foundation and McCallum Theatre. In the past, he served as Non-Executive Chairman at Avery Dennison Corp., Chairman at Quantum Digital Solutions Corp., Director at General Motors Corp., Independent Director at Fluor Corp., Director at Eclipse Aviation Corp., Director at General Motors Co., Director at The TCW Group, Inc., Director at Motors Liquidation Co., Senior Advisor at The Carlyle Group LP (Corporate Private Equity), and Member-Governors Board at The Eli & Edythe L. Broad Foundation. He obtained his undergraduate and graduate degrees from the Massachusetts Institute of Technology. |
| Anthony C. Hooper |
Anthony C. Hooper is currently serving as an Independent Director at MannKind Corp., a Director at the HealthCare Institute of New Jersey, a Director at The American Institute for Stuttering, a Director at The Impact Young Lives Foundation, a Director at Amplity, Inc., an Independent Non-Executive Director at BeiGene Ltd., and an Executive Director at the American Heart Association (New York). In the past, Mr. Hooper held positions as the Chairman of the American Foundation for Suicide Prevention, the Executive Director of Capital Health System, Inc., and a Director at the National Pharmaceutical Council. He also served as the Executive VP-Global Commercial Operations at Amgen, Inc. from 2011 to 2018 and as the Senior Vice President-Global Commercial Operations at Bristol Myers Squibb Co. from 1996 to 2011. Additionally, he held positions at John Wyeth & Brother Ltd. and Wyeth Laboratories, Inc.Mr. Hooper obtained a graduate degree and an MBA from the University of South Africa. |
| Ronald J. Consiglio |
Ronald J. Consiglio is currently serving as an Independent Director at MannKind Corp. since 2003, as well as a Managing Director at Synergy Trading LLC since 1999. He is also a Trustee at Metropolitan West Funds since 2003. Previously, Mr. Consiglio held the position of Chief Executive Officer at Angeles Mortgage Investment Trust from 1993 to 1998. He also served as a Director at Natrol LLC and as the Chief Financial Officer & Senior Vice President at Cantor Fitzgerald & Co. Additionally, he was the Chief Financial Officer & Executive Vice President at Trading Edge, Inc. from 1999 to 2001. Mr. Consiglio was also a Partner at Deloitte Haskins & Sells (US). Mr. Consiglio obtained his undergraduate degree from California State University-Northridge. |
| Sabrina Kay |
Sabrina Kay was the founder of Premier Business Bank (founded in 2006) and Fremont Private Investments, Inc. (founded in 2002) where she holds the titles of Vice Chairman and Chief Executive Officer respectively. Dr. Kay is also the founder of Fremont College, The Art Institute of California-Hollywood, Inc., and Fashion Umbrella LLC. Dr. Kay's current job(s) include being an Independent Director at East West Bancorp, Inc. and East West Bank, as well as an Independent Director at MannKind Corp. She also serves as a Director at Panda Restaurant Group, Inc., Los Angeles Sports & Entertainment Commission, The Hagerty Group LLC, International Medical Corps, The Petersen Automotive Museum, Galvanize, Inc., Yellowbrick Learning, Inc., Portal Schools, and Hagerty, Inc. She is a Strategic Partner at VSS Fund Management LLC and a Member of Beta Gamma Sigma, Inc. and USC Marshall School of Business. Dr. Kay's former job(s) include being the Chairman & Chief Executive Officer of California Design College from 1991 to 2003, Chief Executive Officer of Dale Carnegie of Southern Los Angeles from 2006 to 2020, Chairman of Young Presidents' Organization, Inc., Chairman-Los Angeles of After-School All-Stars from 2004 to 2021, and Director of First Mountain Bank (Big Bear Lake, California), SAE Expression College, and PBB Bancorp. Dr. Kay's education history includes a graduate degree from the University of Pennsylvania, an MBA from the University of Southern California, an undergraduate degree from The California State University, a doctorate from The Wharton School of the University of Pennsylvania, and a graduate degree from the University of Pennsylvania Graduate School of Education. |
| Jennifer Lisa Grancio |
Jennifer Lisa Grancio currently works at Engine No. 1 LLC, as Chief Executive Officer, Fund Management at Engine No. 1 LLC, as Chief Executive Officer from 2020, MannKind Corp., as Independent Director from 2020, and Ethic, Inc., as Director from 2019. Ms. Grancio also formerly worked at Harvest Savings & Wealth Technologies, Inc., as Director, BlackRock Asset Management Deutschland AG, as Head of Distribution iShares from 1998 to 2008, and Pricewaterhousecoopers LLC, as Senior Associate. Ms. Grancio received her undergraduate degree from Stanford University and Masters Business Admin degree from Columbia Business School. |
| Michael A. Friedman |
Dr. Michael A. Friedman is a Partner & Director at Pure Green Agriculture, Inc., a Managing Partner at Ignite Farm LLC, an Independent Director at MannKind Corp., a Chief Executive Officer-Emeritus at City of Hope National Medical Center, an Associate Director at National Cancer Institute and an Independent Non-Executive Director at Smith & Nephew A/S (Denmark). He is on the Board of Directors at FaceTec, Inc., Sermonix Pharmaceuticals LLC, Pure Green Agriculture, Inc., MannKind Corp., California Institute for Regenerative Medicine, Cytovia Holdings, Inc., Cytovia Therapeutics, Inc., Los Angeles Opera Co., Smith & Nephew A/S (Denmark) and Tulane University (Louisiana). Dr. Friedman was previously employed as an Independent Director by Intuitive Surgical, Inc., an Independent Non-Executive Director by Smith & Nephew plc, an Independent Director by Celgene Corp., a Senior Vice President by G.D. Searle & Co., Inc., a SVP-Medical, Public Policy, Research & Development by Pharmacia Corp., a Deputy Commissioner-Operations by US Food & Drug Administration, an Associate Director by National Institutes of Health, a Director-Cancer Research Institute by The University of California, San Francisco, and a Chief Medical Officer-Biomedical Preparedness by Pharmaceutical Research & Manufacturers of America. He also served on the board at Golf Channel, California Healthcare Institute, Darden Restaurants, Inc., Trumpet Advertising Services, Inc., Cancer Research Institute, National Comprehensive Cancer Network, Inc. and Rite Aid Corp. He received his undergraduate degree from Tulane University (Louisiana) and a doctorate degree from The University of Texas Southwestern Medical Center. |
| Christine Ann Mundkur |
Christine Ann Mundkur is an Independent Director at Cardinal Health, Inc. and MannKind Corp. She is also a Director at Lupin Pharmaceuticals, Inc., Nanomi BV, and Lupin, Inc. In the past, she was the President & CEO-North America at Sandoz, Inc., the Chief Executive Officer at Barr Laboratories, Inc., and the Chairman & Chief Executive Officer at Impopharma, Inc. She also served as an Independent Non-Executive Director at Lupin Ltd. and held positions at Uman Pharma, Inc. and Barr Pharmaceuticals, Inc. She received her undergraduate degree from St. Louis University and her graduate degree from Saint Louis University School of Law in 1993. Currently, she holds positions at Cardinal Health, Inc., MannKind Corp., Lupin Pharmaceuticals, Inc., Nanomi BV, and Lupin, Inc. |
